Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol

Investigative Radiology

Volumn 38, Issue 6, 2003, Pages 311-319

  Corot, Claire ^a   Violas, Xavier ^b   Robert, Philippe ^b   Gagneur, Georgia ^b   Port, Marc ^b  

^a Laboratoire Guerbet   (France)

^b NONE

Author keywords

Blood pool agent; MR angiography; MS325; P792; Rabbits; USPIO

Indexed keywords

CHELATE; GADOFOSVESET; GADOLINIUM; GADOMELITOL; GADOMER 17; GADOTERIC ACID; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD SAMPLING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG HALF LIFE; ENDOTHELIUM CELL; EXTRAVASATION; GLOMERULUS FILTRATION RATE; IMAGE ENHANCEMENT; KIDNEY CLEARANCE; MACROMOLECULE; MAGNETIC RESONANCE ANGIOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RABBIT; ULTRAFILTRATION; URINARY EXCRETION; VASCULAR ENDOTHELIUM;

EID: 0038778660     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rli.0000066814.82006.be     Document Type: Conference Paper

References (23)

1. Taupitz M, Schnorr J, Wagner S, et al. Coronary magnetic resonance angiography: experimental evaluation of the new rapid clearance blood pool contrast medium P792. Magn Reson Med. 2001;46:932-938.
2. Marchand B, Douek P, Benderbous S, et al. Pilot MR evaluation of pharmacokinetics and relaxivity of specific blood pool agents for MR angiography. Invest Radiol. 2000;35:41-49.
3. th October 2001.
4. Lin W, Abdendschein D, Celik A, et al. Intravascular contrast agent improves magnetic resonance angiography of carotid arteries in minipigs. J Magn Reson Imaging. 1997;7:963-971.
5. Debiao L, Dolan R, Walovitch R, et al. Three dimensional MRI of coronary arteries using an intravascular contrast agent. Magn Reson Med. 1998;39:1014-1018.
6. Corot C, Violas X, Robert P, et al. Pharmacokinetics of three gadolinium chelates with different molecular sizes shortly after intravenous injection in rabbits: relevance to MR angiography. Invest Radiol. 2000;35:213-218.
7. Corot C, Violas X, Robert P, et al. Arterial concentration profiles of two blood pool agents and Gd-DOTA after intravenous injection in rabbits. Acad Radiol. 2002;9(suppl 1):S137-S139.
8. Bourasset F, Dencausse A, Bourrinet P, et al. Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model. MAGMA. 2001;12: 81-87.
9. Gaillard S, Kubiak C, Stolz C, et al. Safety and pharmacokinetics of P792, a new blood-pool agent: results of clinical testing in nonpatient volunteers. Invest Radiol. 2002;37:161-166.
10. Port M, Corot C, Raynal I, et al. Physicochemical and biological evaluation of P792, a rapid clearance blood pool agent for magnetic resonance imaging. Invest Radiol. 2001;36:445-454.
11. Port M, Corot C, Rousseaux O, et al. P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results. MAGMA. 2001;12:121-127.
12. Misselwitz B, Schmitt-Willich H, Ebert W, et al. Pharmacokinetics of gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA. 2001;12:128-134.
13. Kellar K, Fujii D, Gunther W, et al. NC100150 injection, a preparation of optimised iron oxide nanoparticles for positive-contrast MR angiography. JMRI. 2000;11:488-494.
14. Corot C, Schaefer M, Beauté S, et al. Physical, chemical and biological evaluations of CMD-A2-Gd-DOTA: a new paramagnetic polymer. Acta Radiol. 1997;38(suppl 412):91-99.
15. Lauffer R, Parmelee D, Dunham S, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology. 1998;207:529-538.
16. Parmelee D, Walovitsch C, Ouellet H, et al. Preclinical evaluation of the pharmacokinetics, biodistribution and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol. 1997;32:741-747.
17. Zheng J, Cavagna F, Klocke H, et al. Contrast-enhanced coronary MR angiography: relationship between coronary artery delineation and blood T1. J Magn Reson Imaging. 2001;14:348-354.
18. Bluemke D, Stillman A, Bis K, et al. Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology. 2001;219:114-122.
19. Grist T, Korosec F, Peters D, et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology. 1998;207:539-544.
20. Aime S, Chiaussa M, Digilio G, et al. Contrast agents for magnetic resonance angiographic applications: 1H and 17O NMR relaxometric investigations on two gadolinium(III) DTPA-like chelates endowed with high binding affinity to human serum albumin. J Biol Inorg Chem. 1999;4:766-774.
21. Muller R, Raduchel B, Laurent S, et al. Physicochemical characterization of MS-325, a new gadolinium complex by multinuclear relaxometry. Eur J Inorg Chem. 1999:1949-1955.
22. Johansson L, Fischer S, Lorenz C. Benefit of T1 reduction for magnetic resonance coronary angiography: a numerical simulation and phantom study. J Magn Reson Imaging. 1999;9:552-556.
23. Wikstrom L, Johansson L, Ericsson A, et al. Abdominal vessel enhancement with an ultrasmall, superparamagnetic iron oxide blood pool agent: evaluation of dose and echo time dependence at different field strengths. Acad Radiol. 1999;6:292-298.